Janney Montgomery Scott LLC Bei Gene, Ltd. Transaction History

Janney Montgomery Scott LLC

$35.8 Billion
Q3 2024

A detailed history of Janney Montgomery Scott LLC transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Janney Montgomery Scott LLC holds 1,701 shares of BGNE stock, worth $332,460. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,701

Previous 2,318 26.62%

Holding current value

$332,460

Previous $331,000 15.41%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 29, 2024	SELL	$143.93 - $224.51 $88,804 - $138,522	-617 Reduced 26.62%	1,701 $382,000
Q2 2024 Jul 25, 2024	BUY	$129.52 - $174.32 $4,921 - $6,624	38 Added 1.67%	2,318 $331,000
Q1 2024 May 01, 2024	BUY	$141.8 - $181.47 $125,776 - $160,963	887 Added 63.68%	2,280 $357,000
Q4 2023 Feb 07, 2024	SELL	$158.67 - $201.58 $15,866 - $20,158	-100 Reduced 6.7%	1,393 $251,000
Q3 2023 Nov 08, 2023	SELL	$179.87 - $225.13 $1,079 - $1,350	-6 Reduced 0.4%	1,493 $269,000
Q2 2023 Jul 26, 2023	SELL	$178.3 - $266.78 $69,358 - $103,777	-389 Reduced 20.6%	1,499 $267,000
Q1 2023 Apr 28, 2023	BUY	$215.53 - $274.5 $34,269 - $43,645	159 Added 9.2%	1,888 $407,000
Q4 2022 Feb 01, 2023	SELL	$125.51 - $229.3 $20,834 - $38,063	-166 Reduced 8.76%	1,729 $380,000
Q3 2022 Oct 25, 2022	BUY	$131.8 - $202.24 $19,638 - $30,133	149 Added 8.53%	1,895 $255,000
Q2 2022 Aug 03, 2022	BUY	$121.11 - $216.05 $1,695 - $3,024	14 Added 0.81%	1,746 $283,000
Q1 2022 May 04, 2022	BUY	$146.52 - $269.56 $253,772 - $466,877	1,732 New	1,732 $327,000
Q4 2021 Jan 27, 2022	SELL	$248.56 - $389.34 $158,084 - $247,620	-636 Closed	0 $0
Q3 2021 Oct 29, 2021	BUY	$249.6 - $403.14 $2,246 - $3,628	9 Added 1.44%	636 $231,000
Q2 2021 Jul 26, 2021	BUY	$292.75 - $367.01 $183,554 - $230,115	627 New	627 $215,000

Others Institutions Holding BGNE

# of Institutions

233

Shares Held

41.5M

Call Options Held

81.2K

Put Options Held

82.4K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $20.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janney Montgomery Scott LLC, based on Form 13F filings with the SEC.

News

Stay updated on Janney Montgomery Scott LLC with notifications on news.

Account

Janney Montgomery Scott LLC Bei Gene, Ltd. Transaction History